Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.24.2.u1
Note 3 - Revenue (Tables)
6 Months Ended
Jun. 30, 2024
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended June 30,

   

Six Months Ended June 30,

 
   

2024

   

2023

   

2024

   

2023

 

Pfizer

  $     $ 3,486     $ 6     $ 4,909  

AstraZeneca

          4,056             4,490  

Servier

          (31 )     47       (105 )

Genentech

          12,544             12,697  

Total Revenue

  $     $ 20,055     $ 53     $ 21,991  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

Pfizer

  $ 759     $ 450  

Boston Pharmaceuticals

    85       265  

Total potential milestone payments

  $ 844     $ 715